 | • レポートコード：MRC2-11QY02582 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は抗肥満薬のグローバル市場について調査・分析したレポートです。種類別（末梢作用性抗肥満薬、中枢作用性抗肥満薬）市場規模、用途別（子供、大人）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別抗肥満薬の競争状況、市場シェア ・世界の抗肥満薬市場：種類別市場規模 2015年-2020年（末梢作用性抗肥満薬、中枢作用性抗肥満薬） ・世界の抗肥満薬市場：種類別市場規模予測 2021年-2026年（末梢作用性抗肥満薬、中枢作用性抗肥満薬） ・世界の抗肥満薬市場：用途別市場規模 2015年-2020年（子供、大人） ・世界の抗肥満薬市場：用途別市場規模予測 2021年-2026年（子供、大人） ・北米の抗肥満薬市場分析：米国、カナダ ・ヨーロッパの抗肥満薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの抗肥満薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の抗肥満薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの抗肥満薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Merck、Novo Nordisk、Pfizer、Arena Pharmaceuticals、Roche、GlaxoSmithKline、Orexigen Therapeutics、Vivus、Amylin、Alizyme、Boehringer Ingelheim、Eisai ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Anti-obesity drugs are pharmacological agents that reduce or control weight. These drugs alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. The main treatment modalities for overweight and obese individuals remain dieting and physical exercise.
The report analysts forecast the Global Anti-obesity Drugs market to grow at a CAGR of 41.45 percent over the period 2013-2022.
Market Analysis and Insights: Global Anti-obesity Drugs Market
The global Anti-obesity Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Anti-obesity Drugs Scope and Market Size
Anti-obesity Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-obesity Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Anti-obesity Drugs market is segmented into
Peripherally Acting Anti-obesity Drugs
Centrally Acting Anti-obesity Drugs
Segment by Application, the Anti-obesity Drugs market is segmented into
Kids
Adults
Regional and Country-level Analysis
The Anti-obesity Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Anti-obesity Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Anti-obesity Drugs Market Share Analysis
Anti-obesity Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Anti-obesity Drugs business, the date to enter into the Anti-obesity Drugs market, Anti-obesity Drugs product introduction, recent developments, etc.
The major vendors covered:
Merck
Novo Nordisk
Pfizer
Arena Pharmaceuticals
Roche
GlaxoSmithKline
Orexigen Therapeutics
Vivus
Amylin
Alizyme
Boehringer Ingelheim
Eisai
1 Study Coverage
1.1 Anti-obesity Drugs Product Introduction
1.2 Market Segments
1.3 Key Anti-obesity Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Anti-obesity Drugs Market Size Growth Rate by Type
1.4.2 Peripherally Acting Anti-obesity Drugs
1.4.3 Centrally Acting Anti-obesity Drugs
1.5 Market by Application
1.5.1 Global Anti-obesity Drugs Market Size Growth Rate by Application
1.5.2 Kids
1.5.3 Adults
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Anti-obesity Drugs Market Size, Estimates and Forecasts
2.1.1 Global Anti-obesity Drugs Revenue 2015-2026
2.1.2 Global Anti-obesity Drugs Sales 2015-2026
2.2 Global Anti-obesity Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Anti-obesity Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Anti-obesity Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Anti-obesity Drugs Competitor Landscape by Players
3.1 Anti-obesity Drugs Sales by Manufacturers
3.1.1 Anti-obesity Drugs Sales by Manufacturers (2015-2020)
3.1.2 Anti-obesity Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Anti-obesity Drugs Revenue by Manufacturers
3.2.1 Anti-obesity Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Anti-obesity Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Anti-obesity Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Anti-obesity Drugs Revenue in 2019
3.2.5 Global Anti-obesity Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Anti-obesity Drugs Price by Manufacturers
3.4 Anti-obesity Drugs Manufacturing Base Distribution, Product Types
3.4.1 Anti-obesity Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Anti-obesity Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Anti-obesity Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Anti-obesity Drugs Market Size by Type (2015-2020)
4.1.1 Global Anti-obesity Drugs Sales by Type (2015-2020)
4.1.2 Global Anti-obesity Drugs Revenue by Type (2015-2020)
4.1.3 Anti-obesity Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Anti-obesity Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Anti-obesity Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Anti-obesity Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Anti-obesity Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Anti-obesity Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Anti-obesity Drugs Market Size by Application (2015-2020)
5.1.1 Global Anti-obesity Drugs Sales by Application (2015-2020)
5.1.2 Global Anti-obesity Drugs Revenue by Application (2015-2020)
5.1.3 Anti-obesity Drugs Price by Application (2015-2020)
5.2 Anti-obesity Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Anti-obesity Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Anti-obesity Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Anti-obesity Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Anti-obesity Drugs by Country
6.1.1 North America Anti-obesity Drugs Sales by Country
6.1.2 North America Anti-obesity Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Anti-obesity Drugs Market Facts & Figures by Type
6.3 North America Anti-obesity Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Anti-obesity Drugs by Country
7.1.1 Europe Anti-obesity Drugs Sales by Country
7.1.2 Europe Anti-obesity Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Anti-obesity Drugs Market Facts & Figures by Type
7.3 Europe Anti-obesity Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Anti-obesity Drugs by Region
8.1.1 Asia Pacific Anti-obesity Drugs Sales by Region
8.1.2 Asia Pacific Anti-obesity Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Anti-obesity Drugs Market Facts & Figures by Type
8.3 Asia Pacific Anti-obesity Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Anti-obesity Drugs by Country
9.1.1 Latin America Anti-obesity Drugs Sales by Country
9.1.2 Latin America Anti-obesity Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Anti-obesity Drugs Market Facts & Figures by Type
9.3 Central & South America Anti-obesity Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Anti-obesity Drugs by Country
10.1.1 Middle East and Africa Anti-obesity Drugs Sales by Country
10.1.2 Middle East and Africa Anti-obesity Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Anti-obesity Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Anti-obesity Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Description and Business Overview
11.1.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Merck Anti-obesity Drugs Products Offered
11.1.5 Merck Related Developments
11.2 Novo Nordisk
11.2.1 Novo Nordisk Corporation Information
11.2.2 Novo Nordisk Description and Business Overview
11.2.3 Novo Nordisk Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Novo Nordisk Anti-obesity Drugs Products Offered
11.2.5 Novo Nordisk Related Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description and Business Overview
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Anti-obesity Drugs Products Offered
11.3.5 Pfizer Related Developments
11.4 Arena Pharmaceuticals
11.4.1 Arena Pharmaceuticals Corporation Information
11.4.2 Arena Pharmaceuticals Description and Business Overview
11.4.3 Arena Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Arena Pharmaceuticals Anti-obesity Drugs Products Offered
11.4.5 Arena Pharmaceuticals Related Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Description and Business Overview
11.5.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Roche Anti-obesity Drugs Products Offered
11.5.5 Roche Related Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Corporation Information
11.6.2 GlaxoSmithKline Description and Business Overview
11.6.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.6.4 GlaxoSmithKline Anti-obesity Drugs Products Offered
11.6.5 GlaxoSmithKline Related Developments
11.7 Orexigen Therapeutics
11.7.1 Orexigen Therapeutics Corporation Information
11.7.2 Orexigen Therapeutics Description and Business Overview
11.7.3 Orexigen Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Orexigen Therapeutics Anti-obesity Drugs Products Offered
11.7.5 Orexigen Therapeutics Related Developments
11.8 Vivus
11.8.1 Vivus Corporation Information
11.8.2 Vivus Description and Business Overview
11.8.3 Vivus Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Vivus Anti-obesity Drugs Products Offered
11.8.5 Vivus Related Developments
11.9 Amylin
11.9.1 Amylin Corporation Information
11.9.2 Amylin Description and Business Overview
11.9.3 Amylin Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Amylin Anti-obesity Drugs Products Offered
11.9.5 Amylin Related Developments
11.10 Alizyme
11.10.1 Alizyme Corporation Information
11.10.2 Alizyme Description and Business Overview
11.10.3 Alizyme Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Alizyme Anti-obesity Drugs Products Offered
11.10.5 Alizyme Related Developments
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Description and Business Overview
11.1.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Merck Anti-obesity Drugs Products Offered
11.1.5 Merck Related Developments
11.12 Eisai
11.12.1 Eisai Corporation Information
11.12.2 Eisai Description and Business Overview
11.12.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Eisai Products Offered
11.12.5 Eisai Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Anti-obesity Drugs Market Estimates and Projections by Region
12.1.1 Global Anti-obesity Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Anti-obesity Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Anti-obesity Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Anti-obesity Drugs Sales Forecast (2021-2026)
12.2.2 North America: Anti-obesity Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Anti-obesity Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Anti-obesity Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Anti-obesity Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Anti-obesity Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Anti-obesity Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Anti-obesity Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Anti-obesity Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Anti-obesity Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Anti-obesity Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Anti-obesity Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Anti-obesity Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Anti-obesity Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Anti-obesity Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Anti-obesity Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Anti-obesity Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Anti-obesity Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Anti-obesity Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Anti-obesity Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Anti-obesity Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Anti-obesity Drugs Market Segments
Table 2. Ranking of Global Top Anti-obesity Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Anti-obesity Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Peripherally Acting Anti-obesity Drugs
Table 5. Major Manufacturers of Centrally Acting Anti-obesity Drugs
Table 6. Global Anti-obesity Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 7. Global Anti-obesity Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 8. Global Anti-obesity Drugs Sales by Regions 2015-2020 (K Units)
Table 9. Global Anti-obesity Drugs Sales Market Share by Regions (2015-2020)
Table 10. Global Anti-obesity Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Anti-obesity Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 12. Global Anti-obesity Drugs Sales Share by Manufacturers (2015-2020)
Table 13. Global Anti-obesity Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Anti-obesity Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-obesity Drugs as of 2019)
Table 15. Anti-obesity Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Anti-obesity Drugs Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Anti-obesity Drugs Price (2015-2020) (USD/Unit)
Table 18. Anti-obesity Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Anti-obesity Drugs Product Type
Table 20. Date of International Manufacturers Enter into Anti-obesity Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Anti-obesity Drugs Sales by Type (2015-2020) (K Units)
Table 23. Global Anti-obesity Drugs Sales Share by Type (2015-2020)
Table 24. Global Anti-obesity Drugs Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Anti-obesity Drugs Revenue Share by Type (2015-2020)
Table 26. Anti-obesity Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 27. Global Anti-obesity Drugs Sales by Application (2015-2020) (K Units)
Table 28. Global Anti-obesity Drugs Sales Share by Application (2015-2020)
Table 29. North America Anti-obesity Drugs Sales by Country (2015-2020) (K Units)
Table 30. North America Anti-obesity Drugs Sales Market Share by Country (2015-2020)
Table 31. North America Anti-obesity Drugs Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Anti-obesity Drugs Revenue Market Share by Country (2015-2020)
Table 33. North America Anti-obesity Drugs Sales by Type (2015-2020) (K Units)
Table 34. North America Anti-obesity Drugs Sales Market Share by Type (2015-2020)
Table 35. North America Anti-obesity Drugs Sales by Application (2015-2020) (K Units)
Table 36. North America Anti-obesity Drugs Sales Market Share by Application (2015-2020)
Table 37. Europe Anti-obesity Drugs Sales by Country (2015-2020) (K Units)
Table 38. Europe Anti-obesity Drugs Sales Market Share by Country (2015-2020)
Table 39. Europe Anti-obesity Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Anti-obesity Drugs Revenue Market Share by Country (2015-2020)
Table 41. Europe Anti-obesity Drugs Sales by Type (2015-2020) (K Units)
Table 42. Europe Anti-obesity Drugs Sales Market Share by Type (2015-2020)
Table 43. Europe Anti-obesity Drugs Sales by Application (2015-2020) (K Units)
Table 44. Europe Anti-obesity Drugs Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Anti-obesity Drugs Sales by Region (2015-2020) (K Units)
Table 46. Asia Pacific Anti-obesity Drugs Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Anti-obesity Drugs Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Anti-obesity Drugs Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Anti-obesity Drugs Sales by Type (2015-2020) (K Units)
Table 50. Asia Pacific Anti-obesity Drugs Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Anti-obesity Drugs Sales by Application (2015-2020) (K Units)
Table 52. Asia Pacific Anti-obesity Drugs Sales Market Share by Application (2015-2020)
Table 53. Latin America Anti-obesity Drugs Sales by Country (2015-2020) (K Units)
Table 54. Latin America Anti-obesity Drugs Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Anti-obesity Drugs Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Anti-obesity Drugs Revenue Market Share by Country (2015-2020)
Table 57. Latin America Anti-obesity Drugs Sales by Type (2015-2020) (K Units)
Table 58. Latin America Anti-obesity Drugs Sales Market Share by Type (2015-2020)
Table 59. Latin America Anti-obesity Drugs Sales by Application (2015-2020) (K Units)
Table 60. Latin America Anti-obesity Drugs Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Anti-obesity Drugs Sales by Country (2015-2020) (K Units)
Table 62. Middle East and Africa Anti-obesity Drugs Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Anti-obesity Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Anti-obesity Drugs Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Anti-obesity Drugs Sales by Type (2015-2020) (K Units)
Table 66. Middle East and Africa Anti-obesity Drugs Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Anti-obesity Drugs Sales by Application (2015-2020) (K Units)
Table 68. Middle East and Africa Anti-obesity Drugs Sales Market Share by Application (2015-2020)
Table 69. Merck Corporation Information
Table 70. Merck Description and Major Businesses
Table 71. Merck Anti-obesity Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 72. Merck Product
Table 73. Merck Recent Development
Table 74. Novo Nordisk Corporation Information
Table 75. Novo Nordisk Description and Major Businesses
Table 76. Novo Nordisk Anti-obesity Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 77. Novo Nordisk Product
Table 78. Novo Nordisk Recent Development
Table 79. Pfizer Corporation Information
Table 80. Pfizer Description and Major Businesses
Table 81. Pfizer Anti-obesity Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 82. Pfizer Product
Table 83. Pfizer Recent Development
Table 84. Arena Pharmaceuticals Corporation Information
Table 85. Arena Pharmaceuticals Description and Major Businesses
Table 86. Arena Pharmaceuticals Anti-obesity Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 87. Arena Pharmaceuticals Product
Table 88. Arena Pharmaceuticals Recent Development
Table 89. Roche Corporation Information
Table 90. Roche Description and Major Businesses
Table 91. Roche Anti-obesity Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 92. Roche Product
Table 93. Roche Recent Development
Table 94. GlaxoSmithKline Corporation Information
Table 95. GlaxoSmithKline Description and Major Businesses
Table 96. GlaxoSmithKline Anti-obesity Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 97. GlaxoSmithKline Product
Table 98. GlaxoSmithKline Recent Development
Table 99. Orexigen Therapeutics Corporation Information
Table 100. Orexigen Therapeutics Description and Major Businesses
Table 101. Orexigen Therapeutics Anti-obesity Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 102. Orexigen Therapeutics Product
Table 103. Orexigen Therapeutics Recent Development
Table 104. Vivus Corporation Information
Table 105. Vivus Description and Major Businesses
Table 106. Vivus Anti-obesity Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 107. Vivus Product
Table 108. Vivus Recent Development
Table 109. Amylin Corporation Information
Table 110. Amylin Description and Major Businesses
Table 111. Amylin Anti-obesity Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 112. Amylin Product
Table 113. Amylin Recent Development
Table 114. Alizyme Corporation Information
Table 115. Alizyme Description and Major Businesses
Table 116. Alizyme Anti-obesity Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Alizyme Product
Table 118. Alizyme Recent Development
Table 119. Boehringer Ingelheim Corporation Information
Table 120. Boehringer Ingelheim Description and Major Businesses
Table 121. Boehringer Ingelheim Anti-obesity Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 122. Boehringer Ingelheim Product
Table 123. Boehringer Ingelheim Recent Development
Table 124. Eisai Corporation Information
Table 125. Eisai Description and Major Businesses
Table 126. Eisai Anti-obesity Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 127. Eisai Product
Table 128. Eisai Recent Development
Table 129. Global Anti-obesity Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 130. Global Anti-obesity Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 131. Global Anti-obesity Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 132. Global Anti-obesity Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 133. North America: Anti-obesity Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 134. North America: Anti-obesity Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Europe: Anti-obesity Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 136. Europe: Anti-obesity Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 137. Asia Pacific: Anti-obesity Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 138. Asia Pacific: Anti-obesity Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 139. Latin America: Anti-obesity Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 140. Latin America: Anti-obesity Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 141. Middle East and Africa: Anti-obesity Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 142. Middle East and Africa: Anti-obesity Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 143. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 144. Key Challenges
Table 145. Market Risks
Table 146. Main Points Interviewed from Key Anti-obesity Drugs Players
Table 147. Anti-obesity Drugs Customers List
Table 148. Anti-obesity Drugs Distributors List
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-obesity Drugs Product Picture
Figure 2. Global Anti-obesity Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Peripherally Acting Anti-obesity Drugs Product Picture
Figure 4. Centrally Acting Anti-obesity Drugs Product Picture
Figure 5. Global Anti-obesity Drugs Sales Market Share by Application in 2020 & 2026
Figure 6. Kids
Figure 7. Adults
Figure 8. Anti-obesity Drugs Report Years Considered
Figure 9. Global Anti-obesity Drugs Market Size 2015-2026 (US$ Million)
Figure 10. Global Anti-obesity Drugs Sales 2015-2026 (K Units)
Figure 11. Global Anti-obesity Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 12. Global Anti-obesity Drugs Sales Market Share by Region (2015-2020)
Figure 13. Global Anti-obesity Drugs Sales Market Share by Region in 2019
Figure 14. Global Anti-obesity Drugs Revenue Market Share by Region (2015-2020)
Figure 15. Global Anti-obesity Drugs Revenue Market Share by Region in 2019
Figure 16. Global Anti-obesity Drugs Sales Share by Manufacturer in 2019
Figure 17. The Top 10 and 5 Players Market Share by Anti-obesity Drugs Revenue in 2019
Figure 18. Anti-obesity Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 19. Global Anti-obesity Drugs Sales Market Share by Type (2015-2020)
Figure 20. Global Anti-obesity Drugs Sales Market Share by Type in 2019
Figure 21. Global Anti-obesity Drugs Revenue Market Share by Type (2015-2020)
Figure 22. Global Anti-obesity Drugs Revenue Market Share by Type in 2019
Figure 23. Global Anti-obesity Drugs Market Share by Price Range (2015-2020)
Figure 24. Global Anti-obesity Drugs Sales Market Share by Application (2015-2020)
Figure 25. Global Anti-obesity Drugs Sales Market Share by Application in 2019
Figure 26. Global Anti-obesity Drugs Revenue Market Share by Application (2015-2020)
Figure 27. Global Anti-obesity Drugs Revenue Market Share by Application in 2019
Figure 28. North America Anti-obesity Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 29. North America Anti-obesity Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 30. North America Anti-obesity Drugs Sales Market Share by Country in 2019
Figure 31. North America Anti-obesity Drugs Revenue Market Share by Country in 2019
Figure 32. U.S. Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 33. U.S. Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 34. Canada Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 35. Canada Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. North America Anti-obesity Drugs Market Share by Type in 2019
Figure 37. North America Anti-obesity Drugs Market Share by Application in 2019
Figure 38. Europe Anti-obesity Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 39. Europe Anti-obesity Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 40. Europe Anti-obesity Drugs Sales Market Share by Country in 2019
Figure 41. Europe Anti-obesity Drugs Revenue Market Share by Country in 2019
Figure 42. Germany Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 43. Germany Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. France Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 45. France Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. U.K. Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 47. U.K. Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Italy Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 49. Italy Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Russia Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 51. Russia Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Europe Anti-obesity Drugs Market Share by Type in 2019
Figure 53. Europe Anti-obesity Drugs Market Share by Application in 2019
Figure 54. Asia Pacific Anti-obesity Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 55. Asia Pacific Anti-obesity Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 56. Asia Pacific Anti-obesity Drugs Sales Market Share by Region in 2019
Figure 57. Asia Pacific Anti-obesity Drugs Revenue Market Share by Region in 2019
Figure 58. China Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 59. China Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Japan Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 61. Japan Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. South Korea Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 63. South Korea Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. India Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 65. India Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Australia Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 67. Australia Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Taiwan Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 69. Taiwan Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Indonesia Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 71. Indonesia Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Thailand Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 73. Thailand Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Malaysia Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 75. Malaysia Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Philippines Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 77. Philippines Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Vietnam Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 79. Vietnam Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Asia Pacific Anti-obesity Drugs Market Share by Type in 2019
Figure 81. Asia Pacific Anti-obesity Drugs Market Share by Application in 2019
Figure 82. Latin America Anti-obesity Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 83. Latin America Anti-obesity Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 84. Latin America Anti-obesity Drugs Sales Market Share by Country in 2019
Figure 85. Latin America Anti-obesity Drugs Revenue Market Share by Country in 2019
Figure 86. Mexico Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 87. Mexico Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Brazil Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 89. Brazil Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Argentina Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 91. Argentina Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Latin America Anti-obesity Drugs Market Share by Type in 2019
Figure 93. Latin America Anti-obesity Drugs Market Share by Application in 2019
Figure 94. Middle East and Africa Anti-obesity Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 95. Middle East and Africa Anti-obesity Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 96. Middle East and Africa Anti-obesity Drugs Sales Market Share by Country in 2019
Figure 97. Middle East and Africa Anti-obesity Drugs Revenue Market Share by Country in 2019
Figure 98. Turkey Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 99. Turkey Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Saudi Arabia Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 101. Saudi Arabia Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. U.A.E Anti-obesity Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 103. U.A.E Anti-obesity Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Middle East and Africa Anti-obesity Drugs Market Share by Type in 2019
Figure 105. Middle East and Africa Anti-obesity Drugs Market Share by Application in 2019
Figure 106. North America Anti-obesity Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 107. North America Anti-obesity Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 108. Europe Anti-obesity Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 109. Europe Anti-obesity Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Asia Pacific Anti-obesity Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. Asia Pacific Anti-obesity Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Latin America Anti-obesity Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Latin America Anti-obesity Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Middle East and Africa Anti-obesity Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Middle East and Africa Anti-obesity Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Porter's Five Forces Analysis
Figure 117. Channels of Distribution
Figure 118. Distributors Profiles
Figure 119. Bottom-up and Top-down Approaches for This Report
Figure 120. Data Triangulation
Figure 121. Key Executives Interviewed
抗肥満薬（抗肥満薬）の世界市場（～2026年） Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight. These medications alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. Market Analysis and Insights: Global Ant…- 抗肥満療法の世界市場（～2026年） Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways. Geographically, North America captures the largest …
- 抗肥満処方の世界市場（～2026年） Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory …
- 抗糖尿病治療薬の世界市場（～2026年） The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for…
- 抗腫瘍薬の世界市場（～2026年） Tumor is also termed as neoplasm and it is caused by an abnormal proliferation of tissues. This abnormal proliferation can be due to genetic mutations. Tumors can be subcategorized as benign and malignant. Benign is not destructive however, possess a potential to turn into a malignant tumor... It ha…